Fibrous dysplasia should be considered in the differential diagnosis of tumors in the face and skull. The lesion is often present already in childhood and usually is most active during the general body and bone growth period. Microscopically the lesion consists of irregularly calcified and fibrous bone trabeculae. The rate of malignant degeneration is reported to be 0.4%. The main symptom is a unilateral swelling, and the disconfiguration may be remarkable without pain or other obvious symptoms. On roentgenograms the bone at the site of the lesion appears spongy with a homogeneous, fibrous-looking pattern and a thin egg-shell type of boundary. Sometimes, instead, a dissolution of the fibrous connective tissue occurs resulting in cystformations. The treatment is surgical removal of the diseased tissue; radical, mutilating operations are, however, not indicated. Twelve cases are reported. The lesion occurred in 7 males and 5 females, the maxilla was involved in 8 cases, the mandible in 2 cases, the frontal bone in 1 and the temporal bone in 1. The average duration of the illness was 8 years and the average age at onset around 17 years. Pronounced disconfiguration was seen in most cases, and extensive surgery was necessary in 8 of the patients. Malignant degeneration was not seen.

Keywords:
Fibrous dysplasia, Clinical study
This content is only available via PDF.
© 1969 S. Karger AG, Basel
1969
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.